Ab­b­Vie’s last stand: How an Ice­landic bil­lion­aire’s biosim­i­lar has one fi­nal shot to de­throne Hu­mi­ra

When Ab­b­Vie CEO Richard Gon­za­lez sat be­fore the House Com­mit­tee on Over­sight last week, calm­ly fend­ing off ques­tions about his mega-block­buster Hu­mi­ra and its fortress of patents, the fate of any com­pe­ti­tion en­ter­ing the US mar­ket be­fore 2023 seemed all but sealed.

But what none of the rep­re­sen­ta­tives nor their 57-page re­port men­tioned is that there is still one more biosim­i­lar de­vel­op­er that has a shot at win­ning FDA ap­proval for its ver­sion of Hu­mi­ra in Sep­tem­ber, and has yet to set­tle in court with Ab­b­Vie.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER